Triple-Negative Breast Cancer: Not Entirely Negative

被引：0

作者：

Leone, Jose Pablo ^{[1
]}

Puhalla, Shannon ^{[1
,2
]}

机构：

[1] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA

[2] Magee Womens Hosp, Pittsburgh, PA USA

来源：

ONCOLOGY-NEW YORK | 2013年 / 27卷 / 09期

关键词：

PHASE-III; BEVACIZUMAB; EFFICACY;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：856 / +

页数：3

共 18 条

[1]

[Anonymous], 2011, HERED CANCER CLIN PR, DOI DOI 10.1186/1897-4287-9-S2-A4

[2]

APPLEMAN LJ, 2012, J CLIN ONCOL S, V30

[3] Angiogenesis and lymphangiogenesis are downregulated in primary breast cancer [J].

Boneberg, E-M ;

Legler, D. F. ;

Hoefer, M. M. ;

Oehlschlegel, C. ;

Steininger, H. ;

Fuezesi, L. ;

Beer, G. M. ;

Dupont-Lampert, V. ;

Otto, F. ;

Senn, H-J ;

Fuerstenberger, G. .

BRITISH JOURNAL OF CANCER, 2009, 101 (04) :605-614

[4]

Boyle F, 2012, J CLIN ONCOL, V30

[5] RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer [J].

Brufsky, Adam M. ;

Hurvitz, Sara ;

Perez, Edith ;

Swamy, Raji ;

Valero, Vicente ;

O'Neill, Vincent ;

Rugo, Hope S. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) :4286-4293

[6] Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer [J].

Gelmon, K. A. ;

Hirte, H. W. ;

Robidoux, A. ;

Tonkin, K. S. ;

Tischkowitz, M. ;

Swenerton, K. ;

Huntsman, D. ;

Carmichael, J. ;

Macpherson, E. ;

Oza, A. M. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[7]

Herold CI, ONCOLOGY WILLISTON P, V27, P846

[8] A Phase II Trial Expansion Cohort of the PARP Inhibitor Veliparib (ABT888) and Temozolomide in BRCA1/2 Associated Metastatic Breast Cancer. [J].

Isakoff, S. J. ;

Overmoyer, B. ;

Tung, N. M. ;

Gelman, R. S. ;

Habin, K. ;

Qian, J. ;

Giranda, V. ;

Shepherd, S. ;

Garber, J. E. ;

Ellisen, L. W. ;

Winer, E. P. ;

Goss, P. E. .

CANCER RESEARCH, 2011, 71

[9] Comprehensive molecular portraits of human breast tumours [J].

Koboldt, Daniel C. ;

Fulton, Robert S. ;

McLellan, Michael D. ;

Schmidt, Heather ;

Kalicki-Veizer, Joelle ;

McMichael, Joshua F. ;

Fulton, Lucinda L. ;

Dooling, David J. ;

Ding, Li ;

Mardis, Elaine R. ;

Wilson, Richard K. ;

Ally, Adrian ;

Balasundaram, Miruna ;

Butterfield, Yaron S. N. ;

Carlsen, Rebecca ;

Carter, Candace ;

Chu, Andy ;

Chuah, Eric ;

Chun, Hye-Jung E. ;

Coope, Robin J. N. ;

Dhalla, Noreen ;

Guin, Ranabir ;

Hirst, Carrie ;

Hirst, Martin ;

Holt, Robert A. ;

Lee, Darlene ;

Li, Haiyan I. ;

Mayo, Michael ;

Moore, Richard A. ;

Mungall, Andrew J. ;

Pleasance, Erin ;

Robertson, A. Gordon ;

Schein, Jacqueline E. ;

Shafiei, Arash ;

Sipahimalani, Payal ;

Slobodan, Jared R. ;

Stoll, Dominik ;

Tam, Angela ;

Thiessen, Nina ;

Varhol, Richard J. ;

Wye, Natasja ;

Zeng, Thomas ;

Zhao, Yongjun ;

Birol, Inanc ;

Jones, Steven J. M. ;

Marra, Marco A. ;

Cherniack, Andrew D. ;

Saksena, Gordon ;

Onofrio, Robert C. ;

Pho, Nam H. .

NATURE, 2012, 490 (7418) :61-70

[10] Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies [J].

Lehmann, Brian D. ;

Bauer, Joshua A. ;

Chen, Xi ;

Sanders, Melinda E. ;

Chakravarthy, A. Bapsi ;

Shyr, Yu ;

Pietenpol, Jennifer A. .

JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (07) :2750-2767

← 1 2 →